Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028938 | 1.00 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL316656 | 1.00 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL5595647 | 0.95 | PDE5A (0.91) | PDE5APDE6C | |
| SCHEMBL6333003 | 0.94 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL6340439 | 0.94 | PDE5A (0.88) | PDE5APDE6C | |
| SCHEMBL6334181 | 0.93 | PDE5A (0.87) | PDE5APDE6C | |
| SCHEMBL6338367 | 0.92 | PDE5A (0.86) | PDE5APDE6C | |
| Citric Acid SCHEMBL6332216 | 0.92 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL6340273 | 0.92 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL6332752 | 0.91 | PDE5A (0.83) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | claimed |
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2022-10-20 | — | — | US | claimed |
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250073171-A1 | DRUG DELIVERY SYSTEM FOR THE TREATMENT OF FEMALE SEXUAL INTEREST AND AROUSAL DISORDER | Freya Pharma Solutions Holding B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | disclosed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240165032-A1 | DRUG DELIVERY SYSTEM | EB IP HYBRITABS B V (NL) | 2024-05-23 | — | — | US | disclosed |
| EP-3806888-B1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-11666642-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230056856-A1 | COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF TRANSCRIPTION | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220403001-A1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| CN-109414402-B | Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system | EB IP希博里塔布斯有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2022-10-20 | — | — | US | disclosed |
| US-20220175781-A1 | CD40L COMPOSITIONS AND METHODS FOR TUNABLE REGULATION | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11351169-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220170011-A1 | COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF CAS NUCLEASES | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-114174327-A | Compositions and methods for adjustable modulation of CD40L | 黑曜石疗法公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11241485-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | PDE5A 161/4885PDE6C 194/4885 |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | PDE5A 161/4885PDE6C 194/4885 |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | PDE5A 161/4885PDE6C 194/4885 |
| US-11351169-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | PDE5A 161/4885PDE6C 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.